{"id":671402,"date":"2023-10-09T16:30:01","date_gmt":"2023-10-09T16:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=671402"},"modified":"2023-10-09T16:30:01","modified_gmt":"2023-10-09T16:30:01","slug":"behets-disease-pipeline-clinical-trials-studies-emerging-drugs-and-fda-approvals-2023-updated","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/behets-disease-pipeline-clinical-trials-studies-emerging-drugs-and-fda-approvals-2023-updated_671402.html","title":{"rendered":"Beh\u00e7et\u2019s Disease Pipeline, Clinical Trials Studies, Emerging Drugs, and FDA Approvals 2023 (Updated)"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1696841833.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Beh&ccedil;et&rsquo;s Disease Pipeline, Clinical Trials Studies, Emerging Drugs, and FDA Approvals 2023 (Updated)\" src=\"https:\/\/www.abnewswire.com\/uploads\/1696841833.png\" alt=\"Beh&ccedil;et&rsquo;s Disease Pipeline, Clinical Trials Studies, Emerging Drugs, and FDA Approvals 2023 (Updated)\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;Beh&ccedil;et&rsquo;s Disease Pipeline Insight 2023&rdquo; report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Beh&ccedil;et&rsquo;s Disease pipeline landscape. It covers Beh&ccedil;et&rsquo;s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers Beh&ccedil;et&rsquo;s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Beh&ccedil;et&rsquo;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Beh&ccedil;et&rsquo;s Disease pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Beh&ccedil;et&rsquo;s Disease treatment.<\/li>\n<li>The leading companies working in the Beh&ccedil;et&rsquo;s Disease Market include AbbVie, Eisai Co. Ltd, Nobel Pharmaceuticals, Ainos Inc., Amgen, Janssen Korea Ltd, Novartis Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Hoffmann-La Roche, Bristol-Myers Squibb, Abott, Sanguine Biosciences, GlaxoSmithKline, and others.<\/li>\n<li>Promising Behcet&rsquo;s Disease Pipeline Therapies in the various stages of development include Adalimumab, Veldona, Apremilast, Infliximab, Canakinumab, Pentoxifylline, TA-650, AIN457, Cytotoxic Combination, Abatacept, and others.<\/li>\n<li>August 2023: Amgen announced a study of Phases 3 Clinical Trials for Apremilast. The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to &lt; 18 years of age with oral ulcers associated with Beh&ccedil;et&#8217;s disease (BD) through week 12.<\/li>\n<li>August 2023: Ipekyolu Ilac Ltd. Sti announced a study of Phase 2 Clinical Trials for Pentoxifylline and Colchicine. Although Beh&ccedil;et&#8217;s Disease (BD) has no FDA-approved therapies, numerous clinical reports suggest that oral ulcers of BD may resolve when treated with systemic ingested pentoxifylline (PTX). The investigators here propose to investigate the therapeutic potential of PTX dissolved in muco-adherent formulation and directly applied to the oral lesions. This 60 patient proof of concept trial is designed to meet regulatory requirements for safety concerns while at the same time exploring the potential efficacy and clinical utility of this product. The investigators hypothesize that application of topical PTX will accelerate the healing of these lesions in a clinically meaningful way, and further hypothesize that topical PTX can become a valuable adjunct to any other systemic therapy for BD.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in Beh&ccedil;et&rsquo;s Disease Treatment Drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/behcet-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Beh&ccedil;et&rsquo;s Disease Pipeline Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">In the Beh&ccedil;et&rsquo;s Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Beh&ccedil;et&rsquo;s Disease clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Beh&ccedil;et disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Beh&ccedil;et&rsquo;s Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Behcet disease was first described in 1937 by Hulusi Beh&ccedil;et from Istanbul, who described three patients with oral and genital ulcerations, uveitis, and erythema nodosum. Other clinical features were identified later and were added to the disease spectrum. Behcet disease is an auto-inflammatory systemic vasculitis of unknown etiology.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about Beh&ccedil;et&rsquo;s Disease Therapeutics Assessment @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/behcet-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Beh&ccedil;et&rsquo;s Disease Preclinical and Discovery Stage Products<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Beh&ccedil;et&rsquo;s Disease Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Canakinumab: Novartis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Beh&ccedil;et&rsquo;s Disease Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 5+ key companies which are developing the Beh&ccedil;et&rsquo;s Disease therapies. The Beh&ccedil;et&rsquo;s Disease companies which have their Beh&ccedil;et disease drug candidates in the most advanced stage, i.e. Phase II include Novartis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the emerging Beh&ccedil;et&rsquo;s Disease Pipeline Therapies @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/behcet-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Beh&ccedil;et&rsquo;s Disease Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Beh&ccedil;et&rsquo;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Beh&ccedil;et&rsquo;s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Beh&ccedil;et&rsquo;s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>Beh&ccedil;et&rsquo;s Disease Companies- AbbVie, Eisai Co. Ltd, Nobel Pharmaceuticals, Ainos Inc., Amgen, Janssen Korea Ltd, Novartis Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Hoffmann-La Roche, Bristol-Myers Squibb, Abott, Sanguine Biosciences, GlaxoSmithKline, and others.<\/li>\n<li>Behcet&rsquo;s Disease Pipeline Therapies- Adalimumab, Veldona, Apremilast, Infliximab, Canakinumab, Pentoxifylline, TA-650, AIN457, Cytotoxic Combination, Abatacept, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for new drugs for Beh&ccedil;et&rsquo;s Disease Treatment, Visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/behcet-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Beh&ccedil;et&rsquo;s Disease Market Drivers and Barriers, and Future Perspective<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Beh&ccedil;et disease: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Beh&ccedil;et disease&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Canakinumab: Novartis<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Cipargamin: Novartis<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I\/II)<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical Stage Products<\/li>\n<li>KPG612: Kangpu Biopharmaceuticals<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Beh&ccedil;et disease Key Companies<\/li>\n<li>Beh&ccedil;et disease Key Products<\/li>\n<li>Beh&ccedil;et disease- Unmet Needs<\/li>\n<li>Beh&ccedil;et disease- Market Drivers and Barriers<\/li>\n<li>Beh&ccedil;et disease- Future Perspectives and Conclusion<\/li>\n<li>Beh&ccedil;et disease Analyst Views<\/li>\n<li>Beh&ccedil;et disease Key Companies<\/li>\n<li><strong>30.&nbsp;&nbsp; <\/strong>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>For further information on the Beh&ccedil;et&rsquo;s Disease Pipeline therapeutics, reach out to <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/behcet-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Beh&ccedil;et&rsquo;s Disease Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=behets-disease-pipeline-clinical-trials-studies-emerging-drugs-and-fda-approvals-2023-updated\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/ci-tracking\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/ci-tracking<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/ci-tracking\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=behets-disease-pipeline-clinical-trials-studies-emerging-drugs-and-fda-approvals-2023-updated\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Beh&ccedil;et&rsquo;s Disease Pipeline Insight 2023&rdquo; report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Beh&ccedil;et&rsquo;s Disease pipeline landscape. It covers Beh&ccedil;et&rsquo;s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers Beh&ccedil;et&rsquo;s Disease &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/behets-disease-pipeline-clinical-trials-studies-emerging-drugs-and-fda-approvals-2023-updated_671402.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-671402","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/671402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=671402"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/671402\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=671402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=671402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=671402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}